AI Article Synopsis

  • Systemic hematological malignancies can either show specific cutaneous lymphoma or non-specific skin signs, with most patients first diagnosed with lymphomas before skin issues arise.
  • Patients with skin symptoms may face complex diagnostic challenges, as these symptoms can sometimes mask underlying hematological disorders.
  • A report of five patients highlights how thorough interdisciplinary examinations, including histology and molecular analysis, helped identify previously unrecognized systemic malignancies that initially presented only as skin problems.

Article Abstract

Systemic hematological malignancies can present in the skin as specific secondary cutaneous lymphoma or as non-specific skin manifestations. In the majority of cases, patients are first diagnosed with a systemic lymphoma and may subsequently develop skin involvement. Rarely, the cutaneous symptoms precede the diagnosis of systemic hematological disorders. In these patients, cutaneous infiltrates can present a challenge to both the clinician and the pathologist. We report a series of five patients with clinically and histologically heterogeneous characteristics, in which careful diagnostic procedures finally led to the diagnosis of systemic hematological malignancies. Interdisciplinary clinical and laboratory examination, including histological and molecular analysis and imaging rendered possible the diagnosis of the underlying hematological malignancy. The here-described approaches allowed the diagnosis and therapy of so-far unrecognized hematological malignancies in patients initially presenting exclusively with cutaneous symptoms.

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2013.2010DOI Listing

Publication Analysis

Top Keywords

hematological malignancies
16
systemic hematological
12
cutaneous symptoms
8
diagnosis systemic
8
hematological
6
cutaneous
5
cutaneous presentation
4
presentation hematological
4
malignancies
4
systemic
4

Similar Publications

Objective: To apply the Toronto Childhood Cancer Staging Guidelines (TG) and Estimate the Observed Survival Probabilities for Pediatric Patients with Leukemia and Lymphoma.

Methods: Staging at diagnosis was conducted according to tier 2 of the TG. The study cohort included patients aged 0 -19 years from the Population-Based Cancer Registry (PBCR) of Mato Grosso, diagnosed with leukemia and lymphoma between 2008 and 2017, with follow-up until December 31, 2022.

View Article and Find Full Text PDF

Eosinophilia is a notable feature in various hematological malignancies, including specific types of leukemias and lymphomas that may occur in the head and neck. In hematologic malignancies, eosinophilia can be primary, driven by genetic abnormalities, or secondary, resulting from cytokine and chemokine production by the neoplastic cells or the tumor microenvironment. This review examines the association between eosinophilia and head and neck hematolymphoid malignancies including Classic Hodgkin lymphoma, T-cell lymphoblastic leukemia, mature T and NK-cell lymphomas, and Langerhans cell histiocytosis.

View Article and Find Full Text PDF

Docetaxel (DTX) is the preferred chemotherapeutic drug for prostate cancer (Pca), but the emergence of resistance has significantly reduced its efficacy. Polyphyllin VII (PPVII), a small molecule natural product derived from the traditional herb Paris polyphylla, has shown anticancer potential. This study aims to investigate the effects and mechanisms of PPVII combined with DTX in treating Pca.

View Article and Find Full Text PDF

Exploring the efficacy of fluorouracil and platinum based chemotherapy in advanced hepatocellular carcinoma to bridge the treatment gap in resource limited settings.

Sci Rep

January 2025

Division of Medical Oncology, Department of Internal Medicine, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, 93 Jungbu-daero, Paldal-gu, Suwon, 16247, Korea.

Advanced hepatocellular carcinoma (HCC) poses treatment challenges, especially where access to multi-kinase inhibitors and ICIs is limited by high costs and lack of insurance. This study evaluates the effectiveness of 5-fluorouracil (5-FU) plus platinum-based chemotherapy as an alternative systemic treatment for advanced HCC. A retrospective analysis of advanced HCC patients treated with 5-FU plus platinum-based chemotherapy was conducted.

View Article and Find Full Text PDF

Background: Anti-CD19 CAR T-cells have revolutionized outcomes in relapsed/refractory large B-cell lymphomas. Long-term follow-up underscored the role of hematological toxicity in non-relapse mortality, largely driven by infections, leading to the development of the CAR-HEMATOTOX (HT) score for predicting neutropenia. The European scientific community (EHA/EBMT) later reached a consensus, defining a new entity: immune effector cell-associated hematotoxicity (ICAHT).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!